中医临床研究
中醫臨床研究
중의림상연구
CLINICAL JOURNAL OF CHINESE MEDICINE
2014年
22期
67-68
,共2页
复方丹参%纳洛酮%手足口病%儿童%临床疗效
複方丹參%納洛酮%手足口病%兒童%臨床療效
복방단삼%납락동%수족구병%인동%림상료효
Compound Danshen%Naloxone%HFMD%Children%Clinical efficacy
目的:探讨复方丹参联合纳洛酮治疗小儿重症手足口病的疗效。方法:将2009年3月-2013年8月收入郑州市第一人民医院小儿手足口病区的重症手足口病具有神经精神症状患儿120例随机分成治疗组和对照组各60例,对照组使用常规治疗(吸氧、20%甘露醇降颅压、抗感染、营养脑细胞、应用糖皮质激素、应用静注人免疫球蛋白等),治疗组在对照组基础上应用复方丹参联合纳洛酮治疗,观察两组的临床症状、体征变化及住院时间。结果:治疗组疗效优于对照组(P<0.05),患儿临床症状缓解及出院时间明显低于对照组,两组差异有统计学意义(P<0.01)。结论:复方丹参联合纳洛酮治疗治疗小儿重症手足口病疗程短,见效快,值得临床推广应用。
目的:探討複方丹參聯閤納洛酮治療小兒重癥手足口病的療效。方法:將2009年3月-2013年8月收入鄭州市第一人民醫院小兒手足口病區的重癥手足口病具有神經精神癥狀患兒120例隨機分成治療組和對照組各60例,對照組使用常規治療(吸氧、20%甘露醇降顱壓、抗感染、營養腦細胞、應用糖皮質激素、應用靜註人免疫毬蛋白等),治療組在對照組基礎上應用複方丹參聯閤納洛酮治療,觀察兩組的臨床癥狀、體徵變化及住院時間。結果:治療組療效優于對照組(P<0.05),患兒臨床癥狀緩解及齣院時間明顯低于對照組,兩組差異有統計學意義(P<0.01)。結論:複方丹參聯閤納洛酮治療治療小兒重癥手足口病療程短,見效快,值得臨床推廣應用。
목적:탐토복방단삼연합납락동치료소인중증수족구병적료효。방법:장2009년3월-2013년8월수입정주시제일인민의원소인수족구병구적중증수족구병구유신경정신증상환인120례수궤분성치료조화대조조각60례,대조조사용상규치료(흡양、20%감로순강로압、항감염、영양뇌세포、응용당피질격소、응용정주인면역구단백등),치료조재대조조기출상응용복방단삼연합납락동치료,관찰량조적림상증상、체정변화급주원시간。결과:치료조료효우우대조조(P<0.05),환인림상증상완해급출원시간명현저우대조조,량조차이유통계학의의(P<0.01)。결론:복방단삼연합납락동치료치료소인중증수족구병료정단,견효쾌,치득림상추엄응용。
Objective: To observe clinical efficacy of compound Danshen plus naloxone on children serious HFMD disease. Methods: 120 patients were randomly divided into two groups, 60 cases in each. The control group was given conventional therapy, including oxygen inhalation, 20%mannitol to reduce intracranial pressure, anti-infection, nutrition of brain cells, glucocorticoid and human immune globulin administration;the treatment was added compound Danshen plus naloxone more. Changes of clinical symptoms and signs, length of stay were recorded. Results:Clinical efficacy in the treatment was better than that in the control (P<0.05), duration of clinical symptomatic relieving and length of stay in the treatment were shorter than those in the control. The difference was statistically significant (P<0.01). Conclusion: Compound Danshen plus naloxone was effective on pediatric serious HFMD with short course and quick returns, and is worthy of clinical promotion.